NCT06648200View on ClinicalTrials.gov

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 1, 2030

Study Completion Date

September 1, 2030

Conditions

Small Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent

Interventions

DRUG

JS004

Specified dose on specified days.

DRUG

Toripalimab

Specified dose on specified days.

DRUG

Etoposide

Specified dose on specified days.

DRUG

Platinum

Specified dose on specified days.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06648200 - Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter